Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744055 | 0.96 | EPHX2 (0.43) | EPHX2SCN9ADCPSMGLLSCD | |
| SCHEMBL2744486 | 0.82 | KDM4E (0.47) | — | |
| SCHEMBL27739959 | 0.80 | OPRM1 (0.57) | EPHX2SCN9ASCD | |
| SCHEMBL2744706 | 0.79 | AURKA (0.48) | — | |
| SCHEMBL2744540 | 0.77 | OPRM1 (0.43) | SCN9ASCD | |
| SCHEMBL2744099 | 0.76 | OPRM1 (0.39) | SCN9ASCD | |
| SCHEMBL2744601 | 0.75 | ALDH1A1 (0.45) | MGLL | |
| SCHEMBL2744466 | 0.75 | KDM4E (0.54) | — | |
| SCHEMBL2744862 | 0.75 | HRH3 (0.52) | SCN9A | |
| SCHEMBL2743769 | 0.75 | NCF1 (0.45) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-B1 | Compounds and compositions as hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-8178563-B2 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2012-05-15 | — | — | US | claimed |
| EP-2363393-A1 | Compounds and compositions as hedgehog pathway modulators | IRM LLC (BM) | 2011-09-07 | — | — | EP | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | claimed |
| CN-102746285-B | Compounds and compositions as HEDGEHOG pathway modulators | 太阳制药国际公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-2363393-B1 | Compounds and compositions as hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | EPHX2 2601/4885SCN9A 3863/4885DCPS 2742/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | EPHX2 1410/4885SCN9A 2286/4885DCPS 4188/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | EPHX2 2011/4885SCN9A 2609/4885DCPS 3042/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | EPHX2 2011/4885SCN9A 2609/4885DCPS 3042/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | EPHX2 663/4885SCN9A 2395/4885DCPS 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.